ABSTRACT

The post marketing safety reporting for combination products is a crucial aspect of ensuring the continued safety and effectiveness of these complex medical innovations. Combination products, which merge drugs, medical devices, and biologics, present unique challenges in pharmacovigilance due to their diverse components and potential interactions. This abstract provides an overview of the key considerations and requirements for post marketing safety reporting of combination products. Regulatory agencies, such as the FDA in the United States, play a central role in overseeing post marketing surveillance. Manufacturers, healthcare professionals, and consumers are encouraged to report adverse events and safety concerns related to combination products to these agencies. Timely and accurate reporting facilitates the detection of new or rare adverse events, enabling swift risk assessment and management. The complexity of combination products necessitates coordinated efforts among different regulatory divisions responsible for drugs, medical devices, and biologics. Manufacturers must follow distinct reporting guidelines for each constituent part of the combination product. Additionally, combination products subject to Risk Evaluation and Mitigation Strategies (REMS) require compliance with specific safety reporting requirements. Post marketing safety reporting provides valuable insights into the ongoing benefits and risks associated with combination products in real-world settings. Continuous advancements in surveillance methodologies and data analytics enhance the identification of safety signals and the understanding of long-term safety profiles. Keywords: Surveillance, Biologics, Medical devices, FDA, NDA
Publication date: 01/08/2024

https://ijbpas.com/pdf/2024/August/MS_IJBPAS_2024_8272.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.8.8272